Expert network M&A enters phase two: AI tools, corporate buyers, and the bundle play

Phase one of expert network consolidation was a volume game. Phase two is a bundle game. The shift is now visible in two 2026 moves: InnovateMR's acquisition of Ivy Exec, which drags a market-research firm into qualitative B2B expert work, and VisasQ's launch of AI Scout, which opens the firm's internal matching tools to Coleman Research clients without a new deal. One is M&A. One is product. Both point at the same thesis: the buyer that wins phase two sells experts, transcripts, AI synthesis, and a compliance wrapper as one product, to a customer base that has outgrown the long-only hedge fund.

Six years of deals, in one timeline

The roll-up started before most of the current AI vocabulary existed. The shape of it:

• 2020-2021: Third Bridge, AlphaSights, and GLG consolidate the mid-market through quiet bolt-ons. No marquee deals, plenty of team lifts.
• 2022: VisasQ acquires Coleman Research, giving the Tokyo-listed firm a US client book and a Western brand.
• 2024: AlphaSense acquires Tegus, pairing AlphaSense's search-and-summarisation engine with Tegus's expert call library. The transcript library, not the call flow, is the asset.
• 2025: AlphaSense closes a Series E at a USD 4 billion valuation, positioning itself as an AI workflow company that happens to own an expert network.
• 2026: InnovateMR acquires Ivy Exec. VisasQ launches AI Scout for Coleman clients. The product-side moves arrive.

What changed between 2022 and 2026 is the unit of value. In 2022 the asset was the expert roster. By 2026 the asset is the proprietary transcript corpus, because that corpus is what a foundation model needs to be useful in finance without hallucinating.

The buyer mix is no longer hedge-fund-only

For most of the network's history, the customer was a long-only or hedge fund analyst paying per call. That customer still exists, but the growth is elsewhere. Inex One's 2025 report puts the category at roughly 11,200 client firms, a number that only makes sense if you include corporate strategy teams, management consultancies, private equity due diligence shops, and increasingly, in-house competitive intelligence functions at large enterprises.

This matters for two reasons. First, the corporate buyer wants different things from the analyst buyer. The analyst wants 60 minutes with one expert and a clean transcript. The corporate strategist wants to commission a panel, get a synthesis memo, and own the artefact. Second, the corporate buyer is far less price-sensitive on the bundled product than they are on the individual call. A USD 1,500 expert call is a line item. A USD 50,000 quarterly research subscription with experts, transcripts, and AI tools is a budget category.

InnovateMR's Ivy Exec deal reads as a play for that corporate budget category, not the hedge fund call list.

What InnovateMR-Ivy Exec and VisasQ AI Scout actually signal

The two 2026 moves are different mechanisms aimed at the same outcome. InnovateMR went outside its lane, buying a qualitative B2B expert network to graft onto a quantitative market-research business. VisasQ stayed inside its lane and pushed product, exposing internal AI matching to Coleman's existing book.

What to watch in 2026 and 2027

Three signals will tell us which scenario is playing out. First, whether AlphaSense files for an IPO or stays private through another round. Second, whether GLG returns to the IPO conversation or sells to a sponsor. Third, whether any of the AI-native research tools (Hebbia, Rogo, the next Harvey-equivalent for finance) acquire a transcript-rich network. Any one of those moves resolves the bundle question for the rest of the field.